Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Calculators
Our Services
My Account
Do not call
En
Learn about Hindustan Laboratories Limited’s Draft Red Herring Prospectus (DRHP) filing, business operations, financial context, and the proposed utilisation of funds as outlined in public disclosures.
Hindustan Laboratories Limited has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) as part of its plan to raise capital through an initial public offering. The DRHP outlines the company’s pharmaceutical manufacturing operations, business strategy, financial performance, and the broad structure of the proposed public issue.
The DRHP provides an overview of the proposed IPO and sets out the company’s financials, governance framework, and business outlook.
Hindustan Laboratories Limited filed its Draft Red Herring Prospectus with SEBI in January 2026, marking the formal initiation of its IPO process. The filing is currently under regulatory review. Upon receipt of SEBI observations and subsequent approvals, the company is expected to file the Red Herring Prospectus (RHP), announce the price band, and disclose the IPO opening and closing dates.
The equity shares are proposed to be listed on recognised stock exchanges in India, subject to regulatory clearances.
As per the DRHP, the proposed IPO is expected to comprise the following components:
| Particulars | Details |
|---|---|
Issue Type |
Fresh Issue of Equity Shares + Offer for Sale (OFS) |
Face Value |
₹10 |
Issue Size |
1.41 Crore |
Proposed Listing |
NSE and BSE |
Price Band |
To be announced in RHP |
Book Running Lead Managers |
Choice Capital Advisors Pvt Ltd |
Registrar to the Issue |
MUFG Intime India Pvt Ltd |
These details reflect indicative disclosures available at the DRHP stage and are subject to change based on SEBI observations and final approvals.
Hindustan Laboratories Limited is a pharmaceutical company engaged in manufacturing and distribution of pharmaceutical formulations. The company produces a wide range of products including tablets, capsules, syrups, powders, and injectable formulations across multiple therapeutic categories.
Its operations are supported by manufacturing facilities equipped with modern pharmaceutical production technology, quality control systems, and regulatory compliance infrastructure. The company maintains relationships with distributors, retailers, and healthcare providers across India, enabling broad market reach and product distribution.
Hindustan Laboratories operates in India’s growing pharmaceutical sector, supported by increasing healthcare spending, rising demand for affordable medicines, and expansion of pharmaceutical consumption across population segments. Strategic investments in manufacturing capacity, product innovation, and distribution networks support its competitive positioning in the pharmaceutical manufacturing and distribution market.
According to the DRHP, the proceeds from the Fresh Issue are proposed to be utilised towards the following broad objectives:
| Fund Allocation | Purpose |
|---|---|
Capital Expenditure |
Expansion of manufacturing facilities, advanced pharmaceutical production equipment, formulation lines, quality testing laboratories, and manufacturing technology |
Research & Development |
Development of new pharmaceutical formulations, expansion into new therapeutic categories, product innovation, and regulatory approvals |
Working Capital |
Raw material procurement, inventory management, distributor network support, and operational expenses |
Debt Repayment (if any) |
Optimisation of capital structure and reduction in borrowing costs |
General Corporate Purposes |
Administrative flexibility and strategic initiatives |
These objectives aim to enhance manufacturing capacity, expand the pharmaceutical product portfolio, and support long-term growth in India’s pharmaceutical sector.
The DRHP provides an overview of Hindustan Laboratories Limited’s financial performance over recent periods, offering insight into its operational scale.
| Fiscal Year / Period | Revenue (₹ crore) | EBITDA (₹ crore) | Profit After Tax (₹ crore) |
|---|---|---|---|
FY24 |
186.36 |
44.09 |
34.13 |
FY25 |
219.74 |
53.87 |
41.26 |
H1 FY26 |
112.63 |
As per DRHP |
18.20 |
*Detailed year-wise financial statements, including audited figures, are available in the DRHP and should be referred to for complete financial information.
The table below summarises the current status of the IPO process based on publicly available information:
| Milestone / Stage | Date (or Status) | Details |
|---|---|---|
DRHP filed with SEBI |
January 2026 |
Draft Red Herring Prospectus filed for regulatory review |
SEBI observations |
Awaited |
Subject to regulatory review |
SEBI approval |
Awaited |
Post DRHP review |
Red Herring Prospectus (RHP) |
To be announced |
Post SEBI observations |
IPO Opening Date |
To be announced |
Final dates to be declared |
IPO Closing Date |
To be announced |
As per RHP |
Allotment of Shares |
To be announced |
Post IPO closure |
Listing on NSE/BSE |
To be announced |
Post allotment and listing formalities |
Note: Investors should refer to official filings for final IPO dates to learn more about Hindustan Laboratories IPO listing details and price, and listing timelines.
Check other upcoming ipo’s here : Upcoming IPO
This content is for informational purposes only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Sources
LiveMint — IPO News and Updates, https://www.livemint.com/market/ipo
Economic Times — IPO News: Latest IPO News, Upcoming IPO, https://economictimes.indiatimes.com/markets/ipo
Financial Express — IPO News, https://www.financialexpress.com/market/ipo-news/
NDTV Profit — IPOs, https://www.ndtvprofit.com/ipos
Business Today — IPO Corner: Latest IPO News & Analysis, https://www.businesstoday.in/markets/ipo-corner
Hindustan Laboratories Limited filed its Draft Red Herring Prospectus with the Securities and Exchange Board of India on 3 January 2026, formally initiating the regulatory process for its proposed initial public offering in the Indian capital markets.
The Hindustan Laboratories Limited IPO remains at the Draft Red Herring Prospectus review stage, with observations and approvals from the Securities and Exchange Board of India awaited before proceeding to finalise the Red Herring Prospectus and subscription dates.
The Hindustan Laboratories Limited IPO comprises a fresh issue of up to 50 Lakh equity shares alongside an offer for sale of up to 91 Lakh equity shares by existing shareholders, with final allocation detailed in the Red Herring Prospectus.
The equity shares are proposed to be listed on National Stock Exchange and Bombay Stock Exchange, subject to regulatory approvals.
Hindustan Laboratories Limited proposes utilising fresh issue proceeds for funding working capital requirements, manufacturing expansion, research and development initiatives, potential debt repayment, and general corporate purposes to support operational growth.
.jpeg)
250 Views
| 1min read
Posted on 19 Dec
Academy 
.jpeg "image not found"){kind=small}
